In this interview, David Weisburd interviews David Berry, exploring Berry's journey in biotech and venture capital, his insights into building and scaling companies, and his investment strategies. Berry shares his experiences founding multiple companies, including seven unicorns, and emphasizes the importance of perseverance, adapting to new information, and maintaining a strong company culture. He discusses the challenges of changing direction in successful companies, the significance of early-stage company DNA, and the nuances of product-market fit in drug development. Berry also introduces Averin Capital, his new firm focused on health and technology, and shares his perspective on the future of health and personalized medicine, particularly in the context of Alzheimer's disease.
Sign in to continue reading, translating and more.
Continue